FSSAI Cracks Down On Nestle India Over Infant Formula Products; Flags Claims In NAN Excella Pro, Lactogen Pro
18 Sept, 14:01 IST · Plays out over weeks · 2 sources
Food regulator FSSAI has taken legal action against Nestle India over ads for its baby-milk powders NAN and Lactogen, so Nestle shares may wobble while rival Abbott's Similac could gain a few customers.
Key facts
What the reporting establishes, before any reading of it.
- FSSAI cracked down on Nestle India over infant formula products NAN Excella Pro and Lactogen Pro, flagging promotional claims including '5 HMOs' and 'Whey Protein' (NDTV Profit, 18 Sep 2026).
- FSSAI initiated legal action against Nestle for violating infant food advertising regulations; one product sample failed the prescribed Biotin requirement (Hindu BusinessLine, 18 Sep 2026).
- Action targets a marquee infant-nutrition portfolio, creating reputational and sales overhang for NESTLEIND with possible read-through to peers selling infant/child nutrition.
How the news spreads
Step by step — from the first companies it hits to whole sectors.
Who it hits first
- Nestle India's baby-milk powders NAN Excella Pro and Lactogen Pro face FSSAI legal action over ad claims, plus one sample that fell short on Biotin — expect the company to pull or rewrite claims, change pack labels, and sit through weeks of negative headlines.
- No ban or recall has been ordered, so the hit is reputation and legal cost rather than lost sales; infant formula is only one small part of Nestle India's business behind Maggi noodles, dairy and chocolate.
Who may gain
- Abbott India, whose Similac baby formula sits on the same chemist shelves as NAN and Lactogen, may win a few trial-switching parents over the next month or two.
- No other listed company gains meaningfully — broad foods peers like ITC, Hindustan Unilever and Britannia sell no baby formula.
Along the supply chain
Downstream
Chemists, pharmacies and distributors may briefly tilt baby-formula shelf facings and recommendations toward Similac while Nestle headlines run hot.
Upstream
Suppliers of milk solids, packaging and ingredients feeding two baby-formula product lines see effectively no volume change, since production continues and only labels and ads are in question.
Where demand moves
Business
A small share of new parents may switch baby-milk brands from NAN or Lactogen to Similac on pediatrician advice over 1-2 months, but formula buying is sticky and doctor-led, so volumes move slowly and rivals gain only at the margin.
Capital
No sector-wide money rotation is expected: packaged-food shares stay in their defensive bucket, and any Nestle dip is a stock-specific wobble that bargain hunters, not sector sellers, will trade.
How it spreads across sectors
Fast Moving Consumer Goods
FSSAI scrutiny of functional nutrition claims such as HMOs and whey protein sets a precedent that could extend to health drinks and supplements, a mild overhang for claim-heavy brands like Horlicks, Boost and Complan.
Healthcare
Abbott India marginally positive via Similac trial-switching; no wider hospital or pharma read-through.
Commodity angle
Cc skip reason
no_commodity_link
When it plays out
Immediate
In the next few days Nestle shares likely dip 1-3% on sentiment while peers stay flat; watch for the company's first response.
Medium term
Over 1-6 months a fine or settlement and new labels should close the matter with limited lasting effect on earnings, given the small sales share at stake.
Short term
Over 1-4 weeks expect claim withdrawals, label-change plans and clarity on the legal process; the news cycle decides the depth of the dip.